




CHAPTER 5: Searching for Answers and Validation: Australian Women’s 
Experiences of Coping with the Adverse Sexual Effects of Antidepressants. 
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As discussed in Chapter Four, the research identified four discrete but overlapping 
coping strategies namely i)searching; ii) suffering in silence; iii) trying to resolve and 
iv) accepting what is. This chapter explores and expands on one particular theme 
“searching” and provides and details the findings related to women’s experiences of 
searching for answers and validation relating to their concerns. Most women found 
that early interactions with GPs were inadequate, and therefore hindered their 
attempts to prepare for the sexual side effects and adopt strategies to move forward. 
As such, this chapter discusses and contextualises these particular findings for 




















Sexual difficulties relating to selective serotonin reuptake inhibitor (SSRI) medication 
have an impact on quality of life and are a common cause for non- adherence to 
medication. Whilst most research has focused on the prevalence and treatment of 
sexual difficulties relating to SSRIs, little is known about how individuals cope with 
the adverse sexual effects. This qualitative study, using Interpretive 
Phenomenological Analysis (IPA), investigated the experiences of ten Australian 
women currently coping with the adverse sexual effects of this antidepressant by 
conducting semi- structured interviews. This paper presents one major theme from 
the study and reports the findings specifically related to women’s self-reported 
experiences of interacting with general practitioners (GPs) in their search for 
answers and validation of their concerns. Findings from the study add to the current 
literature by providing an insight into how interactions with GPs affect women’s 
abilities to cope with adverse sexual effects. Empathic discussions and shared 
decision making between GPs and women can provide the opportunity to improve 
the management of the adverse sexual effects of SSRIs and may lead to improved 





What is known about this topic? 
Female sexual difficulties associated with selective serotonin reuptake inhibitors are 
well- documented but women’s experiences of coping with such difficulties have not 
been explored. 
What does this paper add? 
This study provides insight into how interactions with GPs affect women’s abilities to 
cope with the adverse sexual effects of selective serotonin reuptake inhibitors, 








Antidepressant prescribing in Australia has increased substantially over the past 
decade. Despite controversy surrounding the influence of the pharmaceutical 
industry, adverse drug effects and questions about efficacy (Fournier et al., 2010; 
Spence, 2013), antidepressants have become the most commonly dispensed 
psychotropic medication in Australia (Stephenson, Karanges & McGregor, 2013). 
Selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed 
category of antidepressant, and according to Stephenson et al., their use doubled in 
Australia between 2000 and 2011. Whilst there have been calls to reconsider 
medication as a first line treatment for mental health problems (Carlat, 2010), an 
increasing reliance on medication and indeed, patient reluctance to discontinue 
medication for fear of relapse (Spence, 2013) have led to an increased focus on the 
management of adverse drug effects.  
Although a number of adverse effects have been associated with SSRIs 
(Moret, Isaac & Briley, 2009), sexual difficulties remain an underestimated but 
important problem (Safarinejad, 2011). Concerns relating to quality of life and 
adherence to medication have prompted an emerging body of research into the 
sexual difficulties associated with this medication; such difficulties were the focus of 
a recent Cochrane review (Taylor et al., 2013). Given that women have higher levels 
of SSRI use (Hollingworth, Burgess & Whiteford, 2010), several studies have 
focused specifically on managing female sexual problems associated with the 
medication (Safarinejad, 2011; Zhang et al., 2010).Whilst such studies have 
identified a number of management and treatment strategies, the evidence to 
support these approaches is somewhat limited (Taylor et al., 2013).  
Therefore, current attention has focused on strengthening the therapeutic 
alliance between GPs and the patient. Researchers have highlighted the importance 
of a patient-centred approach to the management of sexual difficulties, calling for 
GPs and mental health clinicians to inform patients about potential sexual problems 
(Kikuchi, Uchida, Suzuki, Watanabe & Kashima, 2011) and to encourage shared 
decision making with respect to the management of such difficulties (Quinn, Happell 





drawn to the importance of informed consent when prescribing medication and the 
adoption of a patient-centred model (Gopal et al., 2012; van Servellen et al., 2011), 
such approaches have not been widely adopted.  
Indeed, research has shown that treatment emergent sexual problems are 
infrequently discussed by GP’s and mental health clinicians; personal discomfort, 
lack of time or expertise, and the belief that treatment options are limited have been 
cited as prohibitive factors (Goldstein, Lines, Pyke & Scheld, 2009; Quinn et al., 
2011; Shifren et al., 2009). In addition, Quinn et al. (2011) highlighted that fear of 
non-adherence has prompted the deliberate withholding of information about 
adverse sexual effects in spite of findings revealing such knowledge can actually 
improve adherence rates (Smith & Henderson, 2000). Furthermore, women have 
been reported as generally reluctant to seek help for sexual problems citing personal 
embarrassment, lack of time and perceptions that sexual problems are not taken 
seriously as reasons for this lack of disclosure (Macdowall et al., 2010; Shifren et al., 
2009). Subsequently, it has been reported that women who are taking 
antidepressants have been unlikely to report such adverse effects (Kikuchi et al., 
2011).  
 Although there is a growing body of research on the adverse sexual effects of 
SSRIs, there is a dearth of research on women’s self- reported experiences of 
coping. The aim of our study was to complement existing research by using 
Interpretative Phenomenological Analysis (IPA) to explore the subjective 
experiences of coping with sexual difficulties amongst women who chose to continue 
on SSRIs despite adverse drug effects. Within the field of health psychology, IPA 
has been gaining attention as a flexible and inductive research approach which 
allows the researcher to move beyond a biomedical model of disease and illness to 
explore self- reported experiences and meanings that individuals assign to those 
experiences (Brocki & Weardon, 2006; Smith, Flowers & Larkin, 2009). To offer 
detailed, nuanced analyses of lived experience, IPA utilises an idiographic approach 
that focuses on the individual or specific situations either in a single case study or 
through a small number of participants (Larkin, Watts & Clifton, 2006). Unlike other 
qualitative approaches such as grounded theory which use larger sample sizes and 
seek to generate theory (Pringle, Drummond, Mc Lafferty & Hendry, 2011), the 
individual case is central to the inquiry in IPA. The overall analysis remains faithful to 





have recounted their experiences whilst also illustrating more generalised themes 
(Smith, Flowers & Larkin, 2009).  
This paper presents one major theme from the study and reports the findings 
related to women’s experiences of searching for answers and validation relating to 
their concerns. This paper adds to the current literature by bringing to light an 
increased understanding of how interactions with GPs influence women’s abilities to 
cope with adverse sexual effects. 
 
Methods 
Australian women were recruited to this study through homogeneous sampling and 
selection was based on the following inclusion criteria: heterosexual, under 45 years, 
in a relationship and currently taking SSRIs for depression and/or anxiety disorders. 
Participants for this study were recruited via a mental health website 
(depressionnet.com), social media sites and snowballing techniques (Liamputtong, 
2013). As reported by Shifren et al., (2009), women have often been reluctant to seek 
help for sexual problems hence we did not recruit through health professionals or 
clinics. Participant details are provided in Table 1 (pseudonyms have been used to 
protect anonymity). 
 
Table 1. Demographic information.  













De Facto  Bachelor 
Degree 
Charlotte 45 Severe depression  
(Sertraline) 
13 years Married Postgraduate 
Diploma 




Married  Grade 12 
completion 
Julie 44 Severe depression 
(Fluoxetine) 
7 years Married Postgraduate 
Degree 
Lisa 44 Severe depression  
(Sertraline) 






Mandy 38 Moderate depression 
(Escitalopram) 
2 years Married Grade 12 
completion 
Nadia 42 Moderate depression, 
panic disorder 
(Paroxetine) 
12 years Married Postgraduate 
Degree 
Phoebe 40 Mild depression, panic 
disorder 
(Paroxetine) 
13 years Married Grade 12 
completion 














Ten women were included in this study; each woman had made a conscious 
decision to continue medication despite adverse sexual effects. This enabled us to 
focus on coping strategies and explore these strategies in detail.  According to Smith 
et al. (2009, p. 51), given the complexity of most human phenomena, ‘it is more 
problematic to meet IPA’s commitments with a sample size which is too large than 
with one that is too small’. Whilst no definitive criteria exist for sample size in IPA, the 
authors felt a sample of ten women adequately captured patterns of similarity within 
the group whilst recognising the particularities of individual lives.  Whilst it is 
acknowledged that the findings are not able to be generalised, the study provides 
important information about women’s lived experiences.  It also lays the groundwork 
for future research. 
Data were collected through two semi-structured interviews comprising of 
open-ended questions. The interview schedule was informed by the literature review 
and the professional experience of the first author. The data were analysed following 
IPA guidelines put forward by Smith et al. (2009), namely, reading and re-reading the 
transcripts separately for each woman or case, initial noting, developing emergent 
themes, and searching for connection across emergent themes.  The themes that 
emerged from the first interview were discussed during the second interview to check 
the interpretation. The next stage involved looking for recurrent themes across the 








 The four super-ordinate themes were:  i) searching, ii) suffering in silence, iii) trying 
to resolve and iv) accepting what is.  This paper expands on the first major theme, 
‘searching’, as this theme was reported by all the women and has particular 
relevance for improving experiences in a primary care setting. The theme searching, 
included two sub-ordinate themes i) searching for answers and ii) searching for 
validation.  
Searching for answers 
With the exception of one woman, women were not informed about the adverse 
sexual effects of SSRIs when the medication was prescribed, leaving them feeling 
confused and ‘searching for answers’ about the cause of their sexual problems. As 
such, this lack of information left some women feeling angry: 
At one stage, I went to the doctor and said, “You need to see my husband, he 
has bad anxiety and needs this medication”. She said, “Oh the sexual side 
effects are really bad for men”. Nothing about women though. I’d been on them 
for years and she had never spoken about those side effects. Looking back, I 
feel a bit ripped off, yeah, a bit peeved to be honest. (Mandy) 
Despite feelings of anger, a few women reflected on their situation and perceived 
withholding of information about adverse sexual effects to be deliberate, believing 
GPs actively did this to protect their mental health.  Mandy added: 
I wonder if doctors look at women and think if I tell them they might not take 
them. I mean doctors have to consider the children and if a woman comes in 
and says, ‘I’m depressed, it’s just easier to hand over the medication, do you 
know what I mean?  
Interestingly, a few women said they were ‘owed an explanation’ (Helen) and 
emphasised how having information about untoward sexual effects would not have 
deterred them from taking medication.  Helen continued: 
I really hate the fact that no one told me about this [the sexual side effects]. I 
reckon I would have still taken the medication even if I had known what it would 





As the majority of women perceived they did not have a legitimate medical reason 
for their sexual problems, they spent time questioning whether the adverse effects 
were psychological or caused by factors such as weight gain or other aspects related 
to their current relationship. For some women, ‘searching for answers’ continued for 
several years as outlined by Nadia:  
Once I found out that the Aropax was causing the lack of libido, and all the 
other sexual problems, I started to look for remedies to try and resolve the 
problem. Until then, I was just, you know, hiding...I guess. For quite a few years 
I was secretly hoping it would go away.  
Women were often embarrassed about the sexual nature of their problem and felt 
uncomfortable communicating with others, which  affected their ability to seek help. 
For Tahlia, the internet became a source of information:  
I found out about the sexual side effects through my group [mental health 
support group] This guy, in his 50s said something about “... the side effects 
they don’t tell you about” and he mentioned sex problems and libido. That’s 
when I jumped onto the net to find out more. All the information about Zoloft 
and the associated sex problems were on there - that was a turning point in my 
journey.   
In contrast with most of the women’s experiences, Alison, who had received 
information from her GP, talked about feeling prepared. Her experiences highlighted 
the importance of knowing about the adverse sexual effects in advance: 
I remembered exactly what she had told me um, so (pause) I guess to an 
extent it did help because you know I sort of had that awareness up front that 
this could be an issue....when it actually came up as an issue I was kind of a bit 
more prepared for it. If she hadn’t said those couple of sentences to me I would 
be thinking “What the hell is wrong?  What’s going on?  I don’t understand this 
at all?” I’d be pretty confronted and scared by that I guess.  
 
Searching for validation  
Despite being embarrassed about their sexual problems, women described how they 
sought to address their problem by raising issues directly with their GP; however, 
their experiences of not having their concerns validated affected how they coped 






 I went to the doctor in the end and said “My sexual desire is really low and they go 
“yeah, that happens” they kind of shrug their shoulders you know “You can have 
good mental health or good sex but you can’t have both” kind of attitude. What they 
don’t tell you is that this is one of the main things that can tear you apart.  (Phoebe)  
Tahlia, who received a positive reaction, revealed how this helped:   
It really helped to have the doctor support the idea, that yes, this {sexual 
problem} could be a side effect. When I had raised it before, she was a bit non- 
committal about whether it was a side effect, I felt quite relieved to be honest 
when she agreed with me – I knew then that it wasn’t in my head!   
Some women commented that their concerns had not been validated because of 
their gender. These women found it hard to cope with the implication that sex was 
somehow less important for women. As Charlotte explained: 
I felt as though I was the only woman in the Universe who was concerned 
about the sex problems. I really got the impression that I should just put up with 
it, you know, go away and just deal with it. I often wonder if a doctor would treat 
a man the same way?  
Most women reported feeling concerned that GPs believed their problem was 
psychological; this lack of validation by GPs led these women to seek validation 
elsewhere. As Lisa highlighted, ‘it’s the type of problem you keep to yourself’, as 
such, women turned to online support groups, which helped reduce their sense of 
isolation: 
I couldn’t believe it when I found a support group on the net, there were literally 
hundreds of women on there talking about this stuff and feeling distressed 
about it-  just reading their comments, I’m thumping the desk shouting “yes, this 
is me, this is my story”. It was such a good feeling to know I was not alone….. 
(Sonia)  
In contrast, Nadia experienced a positive outcome because her concerns were 
validated. She provided insight into a conversation that gave her perspective and 
helped her to cope with the long-term sexual problems she had been experiencing:    
After a while, I had a long conversation with my GP and he really listened to me 
and helped me to get my head around it all. He said to me “So, how many 
friends at your age with kids, mortgage and busy lives are having amazing sex 
all the time? Maybe you are missing something that’s not a reality anymore”. 






Discussion   
Women found that interactions with GPs when they were initially prescribed the 
SSRIs, set the scene for how they coped with adverse sexual effects.  Most women 
described their experiences as inadequate, and in an attempt to reduce feelings of 
isolation, confusion and distress, they actively tried to make sense of their situation 
and spent prolonged amounts of time searching for an explanation. This hindered 
their attempts to prepare for adverse side effects and adopt strategies that would 
help them to move forward. Our findings support previous research, which found 
withholding information about adverse sexual effects had the potential to increase 
isolation and distress amongst patients and inadvertently damage the therapeutic 
relationship between clinician and patient (Bahrick & Harris, 2009; Higgins, Barker & 
Begley, 2006). Whilst the specific reasons for withholding information were not 
included in the aim of our study, recent literature has identified a number of personal, 
structural and organisational factors that impede or facilitate a proactive discussion 
of sexual problems (Dyer & das Nair, 2013; Quinn et al., 2011). 
 According to Heider’s (1958) attribution theory, people attempt to provide a 
causal explanation for unexpected events; hence, it is not surprising women sought 
a causal explanation for their side effects. Furthermore, Roesch and Weiner (2001) 
reported that having an explanation for an illness or health problem positively affects 
coping and psychological adjustment. Our study also supports this finding; women 
who had positive interactions with GPs, and who were informed about potential 
sexual problems, felt supported and better able to cope. Happell, Manias and Roper 
(2004) concurred and highlighted that patients with mental health problems want to 
know about the adverse drug effects from their medication in order to be better 
prepared. Indeed, several researchers have suggested that increased knowledge 
about the adverse effects of medication may improve patient outcomes in patients 
with mental health problems (Gray, White, Schuklz & Abderhladen, 2010; Quinn et 
al., 2011). Once the women in our study had an explanation for the adverse effects, 
they reported being relieved and able to move forward and adjust to these effects. 
Women have reported that their experiences of not having concerns validated 
also impacted on how they understood and initially coped with their difficulties. In 
some cases, this lack of validation appeared to reinforce the ‘double standard’ 





are similarities between this study and other studies that reported how mental health 
clinicians, in particular, perceive iatrogenic sexual difficulties as a male problem 
(Phillips, 2009; Quinn et al., 2011). Indeed, our findings seem to be consistent with 
one particular study by Higgins et al. (2006), which reported that mental health 
clinicians perceived women to be less concerned about iatrogenic sexual difficulties 
and more willing to tolerate the adverse sexual effects. Our findings suggest that the 
inadvertent reinforcement of traditional sexual scripts had a negative impact on 
women’s coping experiences and acted as a barrier to the therapeutic relationship. 
These findings further support the need for GPs to take a proactive and empathic 
role in discussing sexual problems and to create a safe space for disclosure and 
validation of such problems.  
Conclusion 
The adverse sexual effects resulting from SSRI use impact quality of life and are a 
common cause for non- adherence to medication. Current efforts by GPs to address 
this issue are most likely inadequate and have an impact on how women cope with 
their medication.  In this context, there needs to be a continual shift towards a 
patient-centred approach, which emphasises women’s active participation in 
decisions about their health, and seeks to strengthen the therapeutic alliance. 
Empathic discussions with women and collaborative decision- making can provide 
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